Insulet
PODD
#1959
Rank
$10.65 B
Marketcap
$153.76
Share price
-0.26%
Change (1 day)
-51.44%
Change (1 year)
Categories
Insulet Corporation is an American company that develops and sells medical devices used for the administration of insulin.

P/E ratio for Insulet (PODD)

P/E ratio as of May 2026 (TTM): 35.6

According to Insulet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.6442. At the end of 2025 the company had a P/E ratio of 81.2.

P/E ratio history for Insulet from 2007 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202581.286.02%
202443.7-40.64%
202373.6-98.25%
2022> 1000263.54%
2021> 1000-50.22%
2020> 1000144.34%
2019951-28.06%
2018> 1000-981.33%
2017-150103.03%
2016-73.9152.07%
2015-29.3-40.82%
2014-49.510.8%
2013-44.7127.5%
2012-19.628.34%
2011-15.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
25.4-28.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
22.9-35.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Medtronic
MDT
20.9-41.36%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Eli Lilly
LLY
34.4-3.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Tandem Diabetes Care
TNDM
-4.75-113.32%๐Ÿ‡บ๐Ÿ‡ธ USA
ICU Medical
ICUI
> 1000 17,433.01%๐Ÿ‡บ๐Ÿ‡ธ USA
DexCom
DXCM
24.7-30.72%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.